There is no shortage of success stories among generic-drug makers these days. Yesterday, IVAX
Ivax said that it believes it has first to file status for 100 mg, 300 mg, and 400 mg tablets of the drug, called gabapentin. The company has also filed an abbreviated new drug application (ANDA) for the 600 mg and 800 mg versions of the drug.
The ultimate approval for gabapentin is dependent on the outcome of a legal dispute, as Pfizer has sued both IVAX and Alpharma
Generics have been a hot topic lately. Earlier this month, shares of Watson Pharmaceuticals
Another of IVAX's recent successes came at the end of September, when the company gained tentative U.S. approval to market a generic version of Johnson & Johnson's